Effects of colloid solution on haemostasis;Interactions entre les solutés colloïdes et l'hémostase

Sang Thrombose Vaisseaux

Volumn 14, Issue 7, 2002, Pages 408-416

  Ickx, Brigitte E ^a   Der Linden, Philippe Van ^b  

^a ERASME HOSPITAL   (Belgium)

^b Centre Hospitalier Universitaire de Charleroi   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN; GELATIN SUCCINATE; HETASTARCH; PLASMA SUBSTITUTE; PLASMION; POLYGELINE;

COLLOID; DRUG EFFECT; DRUG MECHANISM; FRANCE; HEMOSTASIS; HUMAN; PHYSICAL CHEMISTRY; REVIEW;

EID: 0036760817     PISSN: 09997385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Choi PT, Yip G, Quinonez LG, Cook DJ. Crystalloids vs colloids in fluids resuscitation: A systematic review. Crit Care Med 1999; 27: 200-10.
2. Boldt J. Volume replacement in the surgical patient: Does the type of solution make a difference? Br J Anaesthesia 2000; 84: 783-93.
3. Clagett GP, Anderson FAJ, Geerts W, et al. Prevention of venous thromboembolism. Chest 1998; 114: 531S-60S.
4. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: Systemic review of randomised controlled trials. BMJ 1998; 317: 235-40.
5. Bryson GL, Choi PT. Best evidence in anesthetic practice: Harm: Albumin neither increases nor decreases mortality in critically ill patients. Can J Anaesth 2002; 49: 620-2.
6. Ljungström KG. Colloid safety: Fact and fiction. Bailliere's Clinical Anesthesiology 1997; 11: 163-77.
7. Ouaknine-Orlando B, Samama CM. Hématocrite et hémostase. In: Samama CM, de Moerloose P, Hardy JF, Sié P, Steib A et le Groupe d'Intérêt en Hémostase Périopératoire, éds. Hémorragies et Thromboses Périopératoires: Approche Pratique. Paris: Masson, 2000: 113-9.
8. De Jonge, Levi M. Effects of different plasma substitutes on blood coagulation: A comparative review. Crit Care Med 2001; 29: 1261-7.
9. Samama CM. Thromboelastography: The next step. Anesth Analg 2001; 92: 563-4.
10. Carteaux JP, Nathan N. Type de chirurgie et hémostase. In: Samama CM, de Moerloose P, Hardy JF, Sié P, Steib A et le Groupe d'Intérêt en Hémostase Périopératoire, éds. Hémorragies et Thromboses Périopératoires: Approche Pratique. Paris: Masson, 2000: 51-62.
11. Tigchelaar I, Gallandat Huet RCG, Korsten J, Boonstra W, van Oeveren W. Hemostatic effects of three colloid plasma substitutes for priming solution in cardiopulmonary bypass. European J Cardioth Surg 1997; 11: 626-32.
12. Galanakis DK. Anticoagulant albumin fragments that bind to fibrinogen/fibrin: Possible implications. Sem Thromb Haemost 1992; 18: 44-52.
13. Kapiotis S, Quehenberger P, Eichler HG, et al. Effect of hydroxyethyl starch on the activity of blood coagulation and fibrinolysis in healthy volunteers: Comparison with albumin. Crit Care Med 1994; 22: 606-12.
14. Boldt J, Zickmann B, Ballesteros BM, Stermann F, Hempelmann G. Influence of five different priming solutions on platelet function in patient undergoing cardiac surgery. Anesth Analg 1992; 74: 219-25.
15. Vogt NH, Bothner U, Lerch G, Lindner KH, Georggieff M. Large dose administration of 6% hydroxyethyl starch 200/0.5 for total hip arthroplasthy: Plasma homeostasis, hemostasis, and renal function compared to use of 5% albumin. Anesth Analg 1996; 83: 262-8.
16. Vogt N, Bothner U, Brinkmann A, de Petriconi R, Georgieff M. Perioperative tolerance to large dose of 6% HES 200/0.5 in major urological procedures compared with 5% albumin. Anaesthesia 1999; 52: 121-7.
17. Kramer GC, Wade CE, Prough DS. Hypertonic saline dextran: Efficacy and regulatory approval. Acta Anesth Scand 1998; 42: 141-4.
18. Battle J, del Rio F, Lopez Fernadez MF, Martin R, Lopez Borrasca A. Effect of dextran on factor VIIl/von Willebrand factor structure and function. Thromb Haemost 1985; 54: 67-9.
19. Samama CM. Dextran and hemostasis, In: Baron JF, eds. Plasma Volume Expansion. Paris: Arnette, Blackwell, 1992: 97-104.
20. Eriksson M, Saldeen T. Effect of dextran on plasma tissue plasminogen activator (t-PA) and plasminogen acticator inhibitor-1 (PAI-1) during surgery. Acta Anaesth Scand 1995; 39: 163-6.
21. Alberth G, Kettise J, Lisander B. Blood loss in prosthetic replacement is not influenced by the ABO blood group. Eur J Surg 2001; 167: 652-5.
22. Flordal PA, Svensson J, Ljungström KG. Effects of desmopressin and dextran on coagulation and fibrinolysis in healthy volonteers. Thrombosis Research 1991; 62: 355-64.
23. De Jongen E, Levi M, Haisch G, et al. Impaired haemotasis by intravenous administration of a gelatin-based plasma expander in human subjects. Thromb Haemost 1998; 79: 286-90.
24. Tabuchi N, De Haan J, Gallandat Huet RCG, Boonstra PW, van Oeveren W. Gelatin use impairs platelet ahesion during cardiac surgery. Thromb Haemost 1995; 74: 1447-51.
25. Evans PA, Glenn JR, Heptinstall S, Madira W. Effects of gelatin-based resuscitation fluids on platelet aggregation. Br J Anaesth 1998; 81: 198-202.
26. Mardel SN, Saunders FM, Allen H, et al. Reduced quality of clot formation with gelatin-based plasma substitutes. Br J Anaesth 1998; 80: 204-7.
27. Karoutsos K, Nathan N, Lahrimi A, et al. Thromboelastogram reveals hypercoagulability after gelatin solution. Br J Anaesth 1999; 82: 175-7.
28. Mortier E, Ongenae M, De Baerdemaeker L, et al. In vitro evaluation of the effect of profound hemodilution with hydroxyethyl starch 6%, modified fluid gelatin 4% and dextran 40 10% on coagulation profile measured by thromboelastography. Anaesthesia 1997; 52: 1061-4.
29. Hobisch-Hagen P, Wirleitner B, Mair J, et al. Consequences of acute normovolemic haemodilution on haemostasis during major orthopaedic surgery. Br J Anaesth 1999; 82: 503-9.
30. Mortelmans YJ, Vernaut G, Verbruggen AM, et al. Effects of 6% Hydroxyethylstarch and 3% Modified Fluid Gelatin on Intravascular Volume and Coagulation during Intraoperafive hemodilution. Anesth Analg 1995; 81: 1235-42.
31. Langeron O, Doelberg M, Ang ET, Bonnet F, Capdevila X, Coriat P. Voluven®, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5. Anesth Analg 2001; 92: 855-62.
32. Haisch G, Boldt J, Krebs C, Suttner S, Lehmann A, Isgro F. Influence of a new hydroxyethyl starch preparation (HES 130/0.4) on coagulation in cardiac surgical patients. J Cardioth Vascular Anesth 2001; 15: 316-21.
33. Treib J, Haass A, Pindur G, Grauer MT, Wenzel E, Schimrigk K. All medium starch are not the same: Influence of the degree of hydroxyethyl substitution of hydroxyethyl starch on plasma volume, hemorrheologic conditions, and coagulation. Transfusion 1996; 36: 450-5.
34. Treib J, Baron JF, Grauer MT, Strauss RG. An international view of hydroxyethyl starches. Intensiv Care Med 1999; 25: 258-68.
35. Strauss RG, Pennell BJ, Stump DC. A randomized, blinded trial comparing the hemostatic effects of pentastarch versus hetastarch. Transfusion 2002; 42: 27-36.
36. Omar MN, Shouk TA, Khaleq MA. Activity of blood coagulation and fibrinolysis during and after hydroxyethyl starch (HES) colloidal volume replacement. Clin Biochemestry 1999; 32: 269-74.
37. Jamnicki M, Bombelli T, Seifert B, Zollinger A, Camenzind V, Pasch T, Spahn D. Lowand medium-molecular weight hydroxyethyl starches. Comparison of their effect on blood coagulation. Anesthesiology 2000; 93: 1231-7.
38. Treib J, Haass A, Pindur G. Coagulation disorders caused by hydroxyethyls starch. Thromb Haemost 1997; 78: 974-83.
39. Gallandat Huet RCG, Siemons AW, Baus D, et al. A novel hydroxyethyl starch (Voluyen®) for effective perioperative plasma volume substitution in cardiac surgery. Can J Anesth 2000; 47: 1207-15.
40. Macintyre E, Mackie IJ, Ho D, Tinker J, Bullen C, Machin SJ. The haemostatic effects of hydroxyethyl starch (HES) used as a volume expander. Intensive Care Med 1985; 11: 300-3.
41. Kominger C, Speiser W, Wojta J. Sandwich ELISA for t-PA antigen employing a monoclonal antibody. Thromb Res 1986; 41: 527-35.
42. Konrad CJ, Markl TJ, Schuepfer GK, Schmeck J, Gerber HR. In vitro effects of different medium molecular hydroxyethyl starch solutions and lactated ringer's solution on coagulation using sonoclot. Anesth Analg 2000; 90: 274-9.
43. Boldt J, Heesen M, Welters I, Padberg W, Martin K, Hempelmann G. Influence of different volume therapies on platelet function in the critical ill. Intensive Care Med 1996; 22: 1075-80.
44. Franz A, Bräunlich P, Gamsjäger Th, Felfernig M, Gustofff B, Kozek-Langenecker SA. The effect of hydroxylethyl starches of varying molecular weights on platelet function. Anesth Analg 2001; 92: 1402-7.
45. Stögermüller B, Stark J, Willschke H, Felfemig M, Hoerauf K, Kozek-Langenecker SA. The effect of hydroxyethyl starch 200 kDa on platelet function. Anesth Analg 2000; 91: 823-7.
46. Treib J, Baron JF. Hydroxydthylamidons: Efetts sur l'hémostase. Ann Fr Anesth Réanim 1998; 17: 72-81.
47. Huraux C, Ankri AA, Eyraud D, et al. Hemostatic changes in patients receiving hydroxyethyl starch: The influence of ABO blood group. Anesth Analg 2001; 92: 1396-401.
48. Lisander B, Hahn R. Hemostasis in patients of different ABO blood groups. Anesth Analg 2002; 95: 254-5.
49. Claes Y, Van-Hemelrijck J, Van-Cerven M, et al. Influence of hydroxyethyl starch on coagulation in patients during the perioperative period. Anesth Analg 1992; 75: 24-30.
50. Conroy JM, Fishman RL, Reeves ST, Pinosky ML, Lazarchik J. The effects of desmopressin and 6% hydroxyethyl starch on FVIII:C. Anesthesia Analg 1996; 83: 804-7.